Combination of dextromethorphan and bupropion for treating depression
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients having mild or moderate hepatic impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
1. A method of treating agitation associated with Alzheimer's disease in a human patient who has moderate hepatic impairment comprising: determining that a human patient has moderate hepatic impairment, defined as Child-Pugh B, and administering twice daily, by mouth, one tablet containing about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide to the human patient who has moderate hepatic impairment and is experiencing agitation associated with Alzheimer's disease, wherein the dextromethorphan AUC 0-12 of the human patient is 85% to 161% of the dextromethorphan AUC 0-12 of human patients with healthy hepatic function.
2. The method of claim 1 , wherein the dextromethorphan AUC 0-12 of the human patient is 117% of the dextromethorphan AUC 0-12 of human patients with healthy hepatic function.
3. The method of claim 1 , wherein the tablet further contains a carbomer homopolymer.
4. The method of claim 1 , wherein the tablet further contains colloidal silicon dioxide.
5. The method of claim 1 , wherein the tablet further contains crospovidone.
6. The method of claim 1 , wherein the tablet further contains glyceryl monocaprylocaprate.
7. The method of claim 1 , wherein the tablet further contains magnesium stearate.
8. The method of claim 1 , wherein the tablet further contains microcrystalline cellulose.
9. The method of claim 1 , wherein the tablet further contains polyvinyl alcohol.
10. The method of claim 1 , wherein the tablet further contains red iron oxide.
11. The method of claim 1 , wherein the tablet further contains sodium lauryl sulfate.
12. The method of claim 1 , wherein the tablet further contains stearic acid.
13. The method of claim 1 , wherein the tablet further contains talc.
14. The method of claim 1 , wherein the tablet further contains titanium dioxide.
15. The method of claim 1 , wherein the tablet further contains yellow iron oxide.
16. The method of claim 1 , wherein the dextromethorphan hydrobromide is in an immediate-release formulation.
17. The method of claim 1 , wherein the bupropion hydrochloride is in an extended-release formulation.
18. The method of claim 1 , wherein the tablet is a bilayer tablet.